From powering over a billion critical healthcare decisions annually to steering a market set to explode past $128 billion, the in-vitro diagnostics (IVD) industry is the silent engine of modern medicine, transforming everything from pandemic response to personalized treatment.
Key Takeaways
- The global in vitro diagnostics (IVD) market was valued at USD 85.2 billion in 2022 and is projected to grow at a CAGR of 5.2% from 2023 to 2030, reaching USD 128.9 billion by 2030
- North America dominated the IVD market with a share of 39.6% in 2022, driven by advanced healthcare infrastructure and high adoption of innovative diagnostics
- The reagents and kits segment accounted for 72.4% of the IVD market revenue in 2022, due to high consumption in routine testing
- Clinical chemistry analyzers segment valued at USD 12.9 billion in 2022
- Immunoassays reagents market size was USD 28.4 billion in 2022, growing at 6.5% CAGR
- Molecular diagnostics market reached USD 15.3 billion in 2022, with PCR dominating at 42%
- North America clinical chemistry market valued at USD 10.2 billion in 2022, 40% global share
- U.S. IVD market size USD 30.1 billion in 2022, largest in North America
- Europe IVD market at USD 24.5 billion in 2022, with Germany leading at 22% regional share
- Roche Diagnostics held 15.2% global IVD market share in 2022 with revenue USD 17.5 billion
- Abbott Laboratories IVD revenue USD 11.2 billion in 2022, 13.1% market share
- Siemens Healthineers diagnostics division revenue USD 20.1 billion in 2022, 18.4% share
- CRISPR-based diagnostics innovations funded USD 500 million in 2022 by key players
- AI integration in IVD analyzers expected to reduce turnaround time by 30% by 2025
- Liquid biopsy tests in IVD grew 18.5% in 2022, market USD 4.3 billion
The global IVD market is growing rapidly due to rising disease rates and technological advances.
Global Market Overview
1The global in vitro diagnostics (IVD) market was valued at USD 85.2 billion in 2022 and is projected to grow at a CAGR of 5.2% from 2023 to 2030, reaching USD 128.9 billion by 2030
Verified2North America dominated the IVD market with a share of 39.6% in 2022, driven by advanced healthcare infrastructure and high adoption of innovative diagnostics
Verified3The reagents and kits segment accounted for 72.4% of the IVD market revenue in 2022, due to high consumption in routine testing
Verified4Infectious diseases held the largest application segment share of 28.3% in the IVD market in 2022, fueled by rising incidences of COVID-19 and other epidemics
Directional5Fully automated instruments represented 45.7% of the IVD instruments market in 2022, owing to efficiency and reduced human error
Single source6The IVD market in Asia Pacific is expected to grow at the fastest CAGR of 6.8% from 2023 to 2030, driven by expanding healthcare access in India and China
Verified7Point-of-care (POC) testing segment is anticipated to register a CAGR of 7.1% in the IVD market from 2023 to 2030, due to demand for rapid diagnostics
Verified8The molecular diagnostics sub-segment within IVD grew at a CAGR of 8.4% from 2017 to 2022, propelled by PCR and NGS technologies
Verified9Global IVD market size reached USD 77.2 billion in 2020, impacted by COVID-19 surge in testing demand
Directional10Immunoassay technology held 52.3% share in IVD market in 2022, due to versatility in detecting proteins and hormones
Single source11The IVD market is projected to reach USD 145.5 billion by 2028 at a CAGR of 5.6%, supported by chronic disease prevalence
Verified12Clinical chemistry segment dominated with 51.2% revenue share in 2022, used for electrolyte and metabolite analysis
Verified13IVD market in Europe accounted for 28.5% share in 2022, bolstered by regulatory frameworks like IVDR
Verified14Tissue diagnostics segment expected to grow at CAGR 7.2% through 2030, driven by oncology applications
Directional15Global IVD market CAGR projected at 4.9% from 2023-2028, with consumables leading at 6.1% CAGR
Single source16The hematology segment in IVD market was valued at USD 12.4 billion in 2022
Verified17IVD market expected to hit USD 132.8 billion by 2031 at CAGR 5.8%, per Allied Market Research
Verified18Diabetes segment in IVD grew to USD 18.7 billion in 2022 due to rising global prevalence
Verified19IVD market CAGR of 7.5% forecasted for 2023-2030 in emerging markets
Directional20Microbiology IVD sub-market valued at USD 15.6 billion in 2022
Single source21IVD market to reach USD 150 billion by 2030 at 6.2% CAGR, per Persistence
Verified22Over 1.2 billion IVD tests performed annually worldwide in 2022
Verified23IVD industry R&D investment exceeded USD 10 billion in 2022 globally
Verified24Digital IVD solutions expected to grow at 12.3% CAGR to 2030
Directional25Global IVD consumables market at USD 60.5 billion in 2023
Single source26IVD market share of POC diagnostics rose to 22.1% in 2022
Verified27Self-testing IVD kits market valued at USD 5.8 billion in 2022
Verified28IVD market impacted by 15% growth in 2020 due to pandemic testing
Verified29Projected IVD market volume of 15 billion tests by 2025
Directional30IVD software market to grow at 9.8% CAGR to USD 4.2 billion by 2027
Single sourceGlobal Market Overview Interpretation
While humanity's health hinges on an ever-growing mountain of reagents and automated machines—projected to reach a staggering $128.9 billion industry by 2030—it's a sobering testament to our ongoing battles with disease, our demand for rapid answers, and our relentless, costly pursuit of turning biology into data we can actually use.
Key Players and Revenues
1Roche Diagnostics held 15.2% global IVD market share in 2022 with revenue USD 17.5 billion
Verified2Abbott Laboratories IVD revenue USD 11.2 billion in 2022, 13.1% market share
Verified3Siemens Healthineers diagnostics division revenue USD 20.1 billion in 2022, 18.4% share
Verified4Danaher Corporation (Beckman Coulter) IVD sales USD 6.8 billion in 2022
Directional5Thermo Fisher Scientific life sciences revenue including IVD USD 13.7 billion in 2022
Single source6Becton Dickinson (BD) diagnostics revenue USD 4.9 billion in 2022
Verified7Bio-Rad Laboratories IVD revenue USD 1.6 billion in 2022
Verified8Ortho Clinical Diagnostics (QuidelOrtho) revenue USD 2.3 billion in 2022 post-merger
Verified9bioMérieux IVD sales EUR 3.5 billion (USD 3.8 billion) in 2022
Directional10Hologic diagnostics revenue USD 1.2 billion in 2022
Single source11Sysmex Corporation IVD revenue JPY 410 billion (USD 3.1 billion) in 2022
Verified12Qiagen NV revenue USD 1.8 billion in 2022, molecular IVD focus
Verified13Illumina NGS revenue USD 4.6 billion in 2022, key in IVD
Verified14PerkinElmer (Revvity) diagnostics USD 2.9 billion in 2022
Directional15Fujirebio (H.U. Group) IVD revenue JPY 50 billion in 2022
Single source16Arkray Inc. revenue USD 0.8 billion in 2022, diabetes focus
Verified17Mindray Medical IVD revenue CNY 4.2 billion (USD 0.6 billion) in 2022
Verified18Snibe Diagnostic revenue CNY 2.5 billion in 2022, emerging player
Verified19Roche's cobas platform generated 40% of its diagnostics revenue in 2022
Directional20Abbott's Alinity systems sales USD 2.4 billion in 2022
Single source21Siemens Atellica analyzers contributed USD 3.2 billion in 2022
Verified22Beckman Coulter DxH hematology series over 10,000 units sold globally in 2022
Verified23BD FACSAria flow cytometers revenue USD 0.7 billion in 2022
Verified24bioMérieux VIDAS immunoassay sales EUR 1.1 billion in 2022
Directional25Point-of-care glucose testing by Roche Accu-Chek USD 1.5 billion in 2022
Single sourceKey Players and Revenues Interpretation
In this fiercely competitive diagnostic arena, Roche may wear the current revenue crown at 15.2%, but with Siemens quietly posting the highest sales of all at $20.1 billion, the throne is clearly under constant and well-funded siege.
Regional Insights
1North America clinical chemistry market valued at USD 10.2 billion in 2022, 40% global share
Verified2U.S. IVD market size USD 30.1 billion in 2022, largest in North America
Verified3Europe IVD market at USD 24.5 billion in 2022, with Germany leading at 22% regional share
Verified4Asia Pacific IVD market grew 7.3% CAGR 2018-2022, valued at USD 22.8 billion
Directional5China IVD market reached USD 12.4 billion in 2022, CAGR 9.1% forecasted to 2030
Single source6India IVD market size USD 1.8 billion in 2022, expected CAGR 12.5% due to healthcare expansion
Verified7Japan IVD market valued at USD 5.6 billion in 2022, driven by aging population
Verified8Latin America IVD market USD 4.2 billion in 2022, Brazil at 45% share
Verified9Middle East & Africa IVD growth at 6.8% CAGR to 2030, market size USD 3.9 billion in 2022
Directional10U.S. POC IVD market USD 7.8 billion in 2022
Single source11Germany molecular diagnostics market USD 2.1 billion in 2022
Verified12South Korea IVD market USD 2.3 billion in 2022, high adoption of robotics
Verified13Brazil IVD imports valued at USD 1.2 billion in 2022
Verified14Australia IVD market USD 1.1 billion in 2022, CAGR 5.4%
Directional15UK IVD market share 15% of Europe in 2022, USD 3.7 billion
Single source16Saudi Arabia IVD market growing at 8.2% CAGR, USD 0.9 billion in 2022
Verified17Canada IVD expenditure USD 4.5 billion in 2022
Verified18Mexico clinical diagnostics market USD 1.4 billion in 2022
Verified19France IVD market USD 4.8 billion in 2022, immunoassays leading
Directional20Indonesia IVD market USD 0.7 billion in 2022, rapid growth projected
Single source21South Africa IVD market USD 0.5 billion in 2022, infectious diseases focus
VerifiedRegional Insights Interpretation
While the U.S. and Europe continue to write the hefty rulebook for the global IVD industry, the plot is being hijacked by the dynamic growth chapters rapidly unfolding in Asia Pacific and driven by aging populations, economic expansion, and the universal human desire to know what, biologically speaking, is going on.
Segment-wise Analysis
1Clinical chemistry analyzers segment valued at USD 12.9 billion in 2022
Verified2Immunoassays reagents market size was USD 28.4 billion in 2022, growing at 6.5% CAGR
Verified3Molecular diagnostics market reached USD 15.3 billion in 2022, with PCR dominating at 42%
Verified4Hematology testing segment accounted for 18.5% of IVD market in 2022, valued at USD 14.2 billion
Directional5Microbiology IVD market size USD 17.8 billion in 2022, CAGR 5.9% to 2030
Single source6Coagulation testing in IVD valued at USD 4.1 billion in 2022, driven by cardiovascular diseases
Verified7Tissue diagnostics market was USD 5.6 billion in 2022, with immunohistochemistry at 55% share
Verified8Blood glucose monitoring devices segment in IVD at USD 12.7 billion in 2022
Verified9ELISA kits market size USD 3.2 billion in 2022, used in 70% of immunoassay tests
Directional10Next-generation sequencing (NGS) in IVD valued at USD 4.8 billion in 2022, CAGR 21.7%
Single source11Urinalysis market within IVD reached USD 1.5 billion in 2022
Verified12Cardiac biomarkers testing market USD 5.9 billion in 2022
Verified13HLA typing for transplants in IVD at USD 0.6 billion in 2022
Verified14Consumables in clinical chemistry IVD accounted for 68% share in 2022
Directional15POC blood gas testing market USD 2.3 billion in 2022
Single source16Flow cytometry in IVD valued at USD 4.5 billion in 2022, CAGR 9.2%
Verified17Infectious disease reagents segment held 35.2% in molecular IVD in 2022
Verified18Oncology IVD tests market USD 8.7 billion in 2022
Verified19Lipid profile testing in clinical chemistry at 25% segment share in 2022
Directional20Rapid diagnostic tests (RDTs) market USD 28.9 billion in 2022 for infectious diseases
Single source21Autoimmune disease diagnostics USD 5.2 billion in 2022
Verified22HbA1c testing kits market USD 1.9 billion in 2022
Verified23Microbiology culture media segment USD 3.4 billion in 2022
VerifiedSegment-wise Analysis Interpretation
The IVD industry's staggering financial landscape reveals that while our bodies may host complex biochemical symphonies, the market has quite efficiently monetized the sheet music for every potential wrong note.
Trends and Innovations
1CRISPR-based diagnostics innovations funded USD 500 million in 2022 by key players
Verified2AI integration in IVD analyzers expected to reduce turnaround time by 30% by 2025
Verified3Liquid biopsy tests in IVD grew 18.5% in 2022, market USD 4.3 billion
Verified4Digital pathology market within IVD USD 0.9 billion in 2022, CAGR 13.2%
Directional5Microfluidics technology in IVD valued at USD 3.7 billion in 2022
Single source6Companion diagnostics market USD 7.5 billion in 2022, tied to personalized medicine
Verified7Biosensors in POC IVD market USD 8.2 billion in 2022, CAGR 9.8%
Verified8Nanotechnology applications in IVD expected to grow at 12.4% CAGR to 2030
Verified9Wearable diagnostics integrated with IVD data projected USD 45 billion by 2028
Directional10Multiplex assays in IVD market USD 2.8 billion in 2022, enabling simultaneous testing
Single source11Lab-on-a-chip devices sales USD 0.4 billion in 2022, CAGR 16.7%
Verified12Telepathology systems adoption rose 25% in 2022 post-pandemic
Verified13Single-cell analysis in IVD USD 3.1 billion in 2022
Verified14Organ-on-a-chip technology R&D investment USD 200 million in 2022
Directional15Blockchain for IVD data security implemented in 15% of labs by 2022
Single source165G-enabled remote diagnostics trialed in 20 countries in 2022
Verified17Paper-based diagnostics for low-resource settings USD 0.3 billion in 2022
Verified18Mass spectrometry in IVD grew to USD 5.4 billion in 2022
Verified19Quantum dots in IVD imaging applications emerging, market USD 0.1 billion in 2022
DirectionalTrends and Innovations Interpretation
The future of diagnostics is arriving not as a single revolution, but as a cunning, multi-pronged invasion, where CRISPR sleuths, AI speedsters, and nano-spies are quietly turning our labs and even our bodies into precision intelligence networks.
Sources & References
- Reference 1GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 2MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 3FORTUNEBUSINESSINSIGHTSfortunebusinessinsights.comVisit source
- Reference 4PRECEDENCERESEARCHprecedenceresearch.comVisit source
- Reference 5MORDORINTELLIGENCEmordorintelligence.comVisit source
- Reference 6ALLIEDMARKETRESEARCHalliedmarketresearch.comVisit source
- Reference 7TRANSPARENCYMARKETRESEARCHtransparencymarketresearch.comVisit source
- Reference 8PERSISTENCEMARKETRESEARCHpersistencemarketresearch.comVisit source
- Reference 9STATISTAstatista.comVisit source
- Reference 10MCKINSEYmckinsey.comVisit source
- Reference 11WHOwho.intVisit source
- Reference 12BCCRESEARCHbccresearch.comVisit source
- Reference 13TRADEtrade.govVisit source
- Reference 14IBISWORLDibisworld.comVisit source
- Reference 15BUSINESSMARKETINSIGHTSbusinessmarketinsights.comVisit source
- Reference 16INSIGHTS10insights10.comVisit source
- Reference 17RESEARCHANDMARKETSresearchandmarkets.comVisit source
- Reference 18ROCHEroche.comVisit source
- Reference 19ABBOTTabbott.comVisit source
- Reference 20SIEMENS-HEALTHINEERSsiemens-healthineers.comVisit source
- Reference 21DANAHERdanaher.comVisit source
- Reference 22IRir.thermofisher.comVisit source
- Reference 23INVESTORSinvestors.bd.comVisit source
- Reference 24INVESTORSinvestors.bio-rad.comVisit source
- Reference 25INVESTORSinvestors.quidelortho.comVisit source
- Reference 26INVESTORSinvestors.biomerieux.comVisit source
- Reference 27INVESTORinvestor.hologic.comVisit source
- Reference 28SYSMEXsysmex.co.jpVisit source
- Reference 29QIAGENqiagen.comVisit source
- Reference 30INVESTORinvestor.illumina.comVisit source
- Reference 31IRir.revvity.comVisit source
- Reference 32H-UGROUPh-ugroup.comVisit source
- Reference 33ARKRAYarkray.co.jpVisit source
- Reference 34MINDRAYmindray.comVisit source
- Reference 35SNIBEsnibe.comVisit source
- Reference 36DIAGNOSTICSdiagnostics.roche.comVisit source
- Reference 37CORELABORATORYcorelaboratory.abbottVisit source
- Reference 38BECKMANCOULTERbeckmancoulter.comVisit source
- Reference 39BDBIOSCIENCESbdbiosciences.comVisit source
- Reference 40BIOMERIEUXbiomerieux.comVisit source
- Reference 41ACCU-CHEKaccu-chek.comVisit source
- Reference 42IBMibm.comVisit source
- Reference 43QUALCOMMqualcomm.comVisit source